Bioqual, Inc. Reports Earnings Results for the Full Year Ended May 31, 2022
September 19, 2022 at 11:18 am EDT
Share
Bioqual, Inc. reported earnings results for the full year ended May 31, 2022. For the full year, the company reported sales was USD 66.15 million compared to USD 57.68 million a year ago. Net income was USD 5.26 million compared to USD 6.33 million a year ago.
Basic earnings per share from continuing operations was USD 5.88 compared to USD 7.08 a year ago. Diluted earnings per share from continuing operations was USD 5.88 compared to USD 7.08 a year ago.
Bioqual, Inc. is engaged in performing contract research services, which is focused on in vivo models of human diseases, including COVID-19, acquired immune deficiency syndrome (AIDS), influenza, Mpox, respiratory syncytial virus (RSV) infection, Flavivirus infections, including zika and dengue, malaria, hepatitis, and cancer. It is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. The Company also performs in vitro contract research services. The in vitro services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation and other cell-based assays. It also provides research services in herpes simplex in rodents, filariasis in rhesus macaques, chikungunya in rodents and macaques and dengue in rodents and macaques.
BIOQUAL, INC. 
